Improving global health
Our faculty researchers study new human vaccines with the ultimate goal of understanding and preventing infectious diseases across the globe. We are particularly interested in new vaccines which hope to prevent or control infectious diseases in developing countries. Our group consists of a diverse team of clinicians, study coordinators, scientists, laboratory personnel, and volunteers. Our human research studies are carefully designed and are performed with rigorous oversight and in the safest possible manner. All studies are approved by the ethics review board (Institutional Review Board, IRB) of the University of Vermont.
Volunteers are central to the mission of the Vaccine Testing Center. We are not currently recruiting healthy adults for inpatient and outpatient vaccine trials. Click here for more information.
Our team runs a fully functioning unit for performing phase I and II vaccine trials and enteric challenge models at the Vaccine Testing Center (VTC). In general, the VTC focuses on the development of vaccines of importance to global health, including rotavirus, typhoid fever, Campylobacter and cholera infections, as well as dengue and other flavivirus diseases.
UVM Vaccine Testing Center answers questions regarding the recent Zika outbreak and the work that will be done here at UVM to assist in developing a vaccine for it.
Researcher/Analyst Ross Colgate of the UVM Vaccine Testing Center was recently interviewed on VPR Vermont Edition regarding the VTC's recent Rotavirus immunology award. Listen to the full interview here.
UVM Vaccine Testing Center receives grant for Rotavirus immunology study from the Bill and Melinda Gates Foundation. For the full article, click here.
The Vaccine Testing Center would like to welcome Dr. Benjamin Lee, and re-welcome Mary Claire Walsh, who rejoins the team as a researcher/analyst after completing P.A. school. Welcome aboard!
Last modified February 05 2016 02:28 PM